Revive Therapeutics Ltd. · CSE:RVV

Revive Therapeutics — Investor Presentation (March 2020)

16 slides from Revive Therapeutics's investor presentation, March 2020

  1. Slide 1: Psychedelic and Cannabis Life Sciences Company

    Slide 1: Psychedelic and Cannabis Life Sciences Company

    Psychedelic and Cannabis Life Sciences Company Corporate Presentation March 2020 Revive Therapeutics Ltd. | Office: 905-605-5535 | E-mail: info@revivethera.com

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward- looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future f

  3. Slide 3: Revive Therapeutics

    Slide 3: Revive Therapeutics

    REVIVE THERAPEUTICS § Emerging cannabis and psychedelic life sciences company § Developing novel cannabis and psychedelic based therapies to treat liver, inflammatory, and rare diseases § Robust cannabis and psychedelic based product portfolio targeting multi-billion market opportunities § Significa

  4. Slide 4: Pharmaceutical Strategy

    Slide 4: Pharmaceutical Strategy

    PHARMACEUTICAL STRATEGY R&D of Psychedelics and Targeting Inflammation Novel Uses, Targeting FDA Designations: Cannabinoids and Rare Diseases Formulations, and Orphan, Fast track, Delivery System Breakthrough therapy and Rare pediatric diseases

  5. Slide 5: Patent Portfolio

    Slide 5: Patent Portfolio

    PATENT PORTFOLIO Psychedelic and Cannabis Based Patent Portfolio Title USPTO No. Status US 8642088 Issued on February 4, 2014 Cannabinoid Delivery System US 9545423 Issued on January 17, 2017 US 10104888 Issued on October 23, 2018 Use of Cannabidiol in the Treatment of Autoimmune Hepatitis US 824217

  6. Slide 6: Delivery Technology

    Slide 6: Delivery Technology

    DELIVERY TECHNOLOGY § Delivering naturally extracted and synthetic psilocybin and cannabinoids § CANNABINOIDS - Novel combination of composites allowing for multiple delivery formats, potential synergistic and therapeutic effects § Tannin (plant-based) - antibacterial, antifungal, antioxidant and wo

  7. Slide 7: Product Pipeline

    Slide 7: Product Pipeline

    PRODUCT PIPELINE Psychedelic and Cannabis Based Rare Disease Focus Stage of Regulatory Product Indication Market Development Status Autoimmune Received FDA + $100M CBD Filing IND Hepatitis Orphan Status 50k US Pop IRI Solid Organ Received FDA + $100M CBD Pre-clinical Transplants Orphan Status 20k US

  8. Slide 8: Liver Disease Opportunity

    Slide 8: Liver Disease Opportunity

    LIVER DISEASE OPPORTUNITY § Potential $19.5Bn market by 2022; affecting +30mm people in U.S. § Focus on Autoimmune Hepatitis (AIH) and Nonalcoholic steatohepatitis (NASH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side e

  9. Slide 9: Inflammatory Skin Disease Opportunity

    Slide 9: Inflammatory Skin Disease Opportunity

    INFLAMMATORY SKIN DISEASE OPPORTUNITY § Inflammatory skin diseases from immune system reactions Psoriasis § Unmet medical need requiring new treatment options • Current treatments are inadequate, have unwanted side effects profiles, and expensive Dermatitis § Dermatitis (Eczema) Market Opportunity •

  10. Slide 10: Psychedelic Opportunity

    Slide 10: Psychedelic Opportunity

    PSYCHEDELIC OPPORTUNITY § Acquired Psilocin Pharma Corp. § PPC has novel methods of production of Psilocybin-based formulations § Developed six unique patent pending formulations for both natural and synthetically derived Psilocybin § Capsules (PSY-0.1), Sublingual Spray (PSY-0.2), Gel Cap (PSY-0.3)

  11. Slide 11: Founder – Psilocin Pharma

    Slide 11: Founder – Psilocin Pharma

    FOUNDER – PSILOCIN PHARMA § Derrick Welsh § 14 years of Health Care experience, with the past 5 years in the Cannabis industry § Worked with several high profile publicly-traded Cannabis companies like Xanthic Bio Pharma and Green Growth Brands § Developed several patent pending formulations such as

  12. Slide 12: Strategic Relationships

    Slide 12: Strategic Relationships

    STRATEGIC RELATIONSHIPS Supply and collaboration Acquired March 2020 Research collaboration of truffles Psychedelic pharma for liver diseases License of cannabidiol for License of cannabinoid Licensed Dealer of treatment of Autoimmune delivery technology medical cannabis Hepatitis (R&D, Testing)

  13. Slide 13: Value Driving Milestones in 2020

    Slide 13: Value Driving Milestones in 2020

    VALUE DRIVING MILESTONES IN 2020 Q1-2020 Complete acquisition of Psilocin Pharma Corp. Q2-2020 Submit IND for Phase 1/2a clinical study for CBD in the treatment of Autoimmune Hepatitis Q3-2020 Pre-IND meeting with FDA for Psilocybin in treatment of mental illness (indication undisclosed) Q2/3-2020 I

  14. Slide 14: Significantly Undervalued

    Slide 14: Significantly Undervalued

    SIGNIFICANTLY UNDERVALUED 3.9 B 105 M 90 M 60 M 5M

  15. Slide 15: Team

    Slide 15: Team

    TEAM Management Board of Directors § Michael Frank § Michael Frank Chairman and CEO Chairman and CEO § Carmelo Marrelli § William Jackson Chief Financial Officer Director § Joshua Herman Director § Christian Scovenna Director § Andrew Lindzon Director

  16. Slide 16: Stock Information

    Slide 16: Stock Information

    STOCK INFORMATION Ticker Symbols RVV (CSE) Share Price CAD $0.075 (March 10, 2020) 52 week High/Low CAD $0.135 / $0.025 Capital Structure 130,411,282 common shares (151,491,991 fully-diluted) Market Cap CAD ~ $10,000,000

Source: Internet Archive copy of revivethera.com

More decks from Revive Therapeutics Ltd.

All 36 Revive Therapeutics decks